WHA68: Global Vaccine Plan Lagging; New Proposal To Lower Prices

68th World Health Assembly Committee A

An assessment of the World Health Organization Global Vaccine Action Plan aimed at delivering vaccination to all and boosting research into new vaccines found implementation to be “far off-track” in some areas. Today at the World Health Assembly, Libya put forward a new proposal at the Assembly to reduce vaccine prices and increase availability in developing countries.

World Health Assembly Opens: Time Of Change At WHO; G-7 Involved

German Chancellor Angela Merkel speaks at WHA 68

“The Ebola outbreak shook this organization to its core,” World Health Organization Director General Margaret Chan said in opening the WHO’s annual assembly today. And the need to better construct the world’s emergency response systems has the biggest economies on the podium, with German Chancellor Angela Merkel speaking as chair of the Group of 7.

WHO Leads Effort To Build R&D Roadmap For Future Epidemics

Panel Chair Barbara Stocking, photo credit John Zaracostas

The World Health Organization is working to learn from the fast response on research and development for Ebola that led to effective treatments in a short time. It hopes that this changes the way R&D for emergency vaccines is done forever.

In ‘Huge’ Move, WHO Adds Key Hepatitis C, Cancer, TB Drugs To Essential Medicines List

happy crowd africa

The World Health Organization today published its updated Model List of Essential Medicines, including high-priced new treatments for hepatitis C, cancers and multi-drug resistant tuberculosis (MDR-TB) that were quickly applauded by the public health advocacy community.

Industry Asks For Clarity On LDC Request To Extend TRIPS Pharma Waiver

medicines for poor

Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry this week stated that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.

Pharma Offers View On How To Slow Antimicrobial Resistance, Boost Research

Bacteria

the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.

Chile: Study On Pharma Patents Shows Foreign Ownership

pills

In Chile, pharmaceutical patents are almost exclusively the domain of foreign companies. Only a subset of drugs is protected by patents, while a much larger number of products is protected by trademarks, a study finds, offering for the first time empirical evidence on the use of primary and secondary patents in Chile.

WHO: Too Few Countries Fighting Antimicrobial Resistance; Global Action Plan Advocates Equitable Access

Antibiotics

The World Health Organization released a report today on countries’ response to the global declining effect of antibiotics on bacteria and microbes, heightened by overuse or misuse of those products. Next month the World Health Assembly will consider a draft global action plan to fight the problem, which includes suggestions for sustainable investment in the area such as de-linking research from price and sales, as well as equitable access to new products.

UAEM Grades US Universities On Research For Neglected Diseases. Spoiler Alert – There’s Room For Improvement

UAEMLogo-2013

Universities play an enormous role in biomedical research in the United States, but are not doing all they can to advance research for neglected diseases or make their innovations available to people who need them most, the student groupUniversities Allied for Essential Medicines (UAEM) said this week. UAEM released the results of its second annual […]

Divide And Conquer: The New US Strategy To Disentangle The TPP Negotiations

Public Citizen TPP ISDS

Burcu Kilic & Pablo Viollier write: Political leaders in Washington and other Trans-Pacific Partnership (TPP) negotiating countries have set the end of May as the latest deadline for completion of the talks. The negotiations have already missed several such deadlines, so who really knows? No one. But there is something we all know: TPP raises significant concerns because negotiations are being held behind closed doors with details kept secret even from the legislatures in TPP countries.